A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
| Autor: | Patrick H. Biggar, Andreas Walper, Frank Leistikow |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Anemia 030232 urology & nephrology 030204 cardiovascular system & hematology Hematocrit Disaccharides Ferric Compounds Gastroenterology Hemoglobins 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine medicine Humans Prospective Studies Aged Aged 80 and over Anemia Iron-Deficiency medicine.diagnostic_test business.industry Transferrin saturation Cumulative dose General Medicine Iron deficiency Middle Aged medicine.disease Tolerability Iron-deficiency anemia Nephrology Hematinics Kidney Failure Chronic Female business Kidney disease |
| Zdroj: | Clinical Nephrology. 86:310-318 |
| ISSN: | 0301-0430 |
| Popis: | AIMS The aim of this study was to investigate the effectiveness, safety, and tolerability of iron isomaltoside in routine practical care of iron deficiency anemia (IDA) in patients with chronic renal failure. METHODS The study included 698 patients with IDA on dialysis or with nondialysis chronic kidney disease (CKD) stages 3 - 5 designated by their physicians for treatment with iron isomaltoside. Data were recorded at baseline and after 3 and 9 months. Effectiveness data included measurement of hemoglobin (Hb), hematocrit, i-iron, transferrin saturation (TSAT), and i-ferritin. Safety data included adverse events and safety laboratory variables. RESULTS Following administration of a mean cumulative dose of 2,574 mg isomaltoside over 9 months, initial average Hb increased from 11.0 g/dL to 11.6 g/dL, TSAT from 19.4% to 28.3%, and i-ferritin from 320 µg/L to 642 µg/L, demonstrating a positive effect of iron isomaltoside on iron deficiency. In addition, there was a significant reduction in the use of erythropoiesis-stimulating agents (ESAs) (regarding epoetin α, initial mean dose 40,688 IU/month, final dose 35,665 IU/month, -13.7%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|